Pacira reported $34.68B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Astellas Pharma JPY 3.53T 164.74B Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Cara Therapeutics USD 23.53M 2.28M Sep/2026
Coherus Biosciences USD 191.18M 74.84M Jun/2026
Heron Therapeutics USD 230.45M 21.81M Sep/2026
Ironwood Pharmaceuticals USD 290.59M 5.46M Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Ligand Pharmaceuticals USD 2.24B 51.59M Sep/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Novo Nordisk DKK 594.94B 35.72B Jun/2026
Omeros USD 200.57M 34.59M Jun/2025
Pacira USD 34.68B 33.44B Sep/2026
Perrigo USD 7.48B 124.6M Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Supernus Pharmaceuticals USD 1.4B 30.42M Sep/2026
Teva Pharmaceutical Industries USD 40.04B 185M Sep/2026
Xeris Pharmaceuticals USD 423.22M 11.31M Sep/2026
Zoetis USD 15.09B 11M Sep/2026